Disease Characteristics and Change in Arthritis Activity according to Treatment in Hepatitis B Surface Antigen-positive Rheumatoid Arthritis Patients: a Retrospective Chart Review Study

Yeonghee Eun,1 In Young Kim,1 Hyemin Jeong,2 Hyungjin Kim,1 Jaejoon Lee,1 Moon Seok Choi,1 Eunmi Koh1, and Hoon-Suk Cha1

1Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
2Department of Medicine, Soonchunhyang University College of Medicine, Bucheon, Korea

ABSTRACT

Background: Rheumatoid arthritis (RA) treatment may differ according to hepatitis B state and consequently may bring about different arthritis outcomes. However, whether hepatitis B affects treatment outcome remains unclear. We investigated differences in change in arthritis activity between RA patients according to concomitant hepatitis B virus infection.

Methods: A retrospective medical chart review was performed by two rheumatologic fellows using single center data, from January 2000 to March 2015. Among RA patients older than 18 years, patients with comorbidities that could affect RA treatment aside from hepatitis B were excluded. Using 1:3 propensity score matching, 40 hepatitis B virus surface antigen (HBsAg)-positive patients and 112 HBsAg-negative patients were included in the study. Data were collected longitudinally using standardized electronic forms. The longitudinal relationship between HBsAg-positivity and RA activity was analyzed using generalized estimating equations.

Results: RA activity showed time-dependent improvement. Reductions of swollen joint count over time were significantly larger in the HBsAg-negative group. However, changes in disease activity score in 28 joints with three variables (DAS28-3), tender joint count, erythrocyte sedimentation rate and C-reactive protein level did not differ between the groups. There were no differences in alanine aminotransferase level. HBsAg-positive patients were less likely to receive methotrexate (odds ratio [OR], 0.09; 95% confidence interval [CI], 0.04–0.19; P < 0.001) and more likely to receive sulfasalazine (OR, 3.67; 95% CI, 1.94–6.95; P < 0.001).

Conclusion: RA medication use varied according to HBsAg-positivity. However, improvement in RA activity was not significantly affected by concomitant hepatitis B infection.

Keywords: Rheumatoid Arthritis; Hepatitis B; Disease Activity Score
INTRODUCTION

Hepatitis B virus (HBV), a DNA virus with a human-only reservoir, is a serious global health concern. The worldwide prevalence of HBV infection is estimated to be 3.61%, and it is similar in rheumatoid arthritis (RA) patients. Coexistence of RA with hepatitis B makes the treatment of RA risky because some disease-modifying antirheumatic drugs (DMARDs) such as methotrexate and leflunomide may cause hepatotoxicity and some drugs that affect immune response can lead to reactivation of HBV. Consequently, RA treatment may differ according to hepatitis B status and this could lead to different arthritis outcomes.

Previous studies of RA patients with concomitant hepatitis B tended to focus on the safety of arthritis medications and reactivation of hepatitis. Only a small number of studies addressed differences in disease characteristics and treatment patterns of RA in relation to hepatitis B status. However, whether hepatitis B affects treatment outcomes such as RA disease activity remains unclear.

In this study, we investigated potential variation in changes in disease activity markers upon treatment between RA patients based on their concomitant hepatitis B status. We employed hepatitis B virus surface antigen (HBsAg) as a serological marker of HBV infection.

METHODS

Study population

A retrospective medical chart review was performed by two rheumatologic fellows using single center data, from 1 January 2000 to 31 March 2015. Patients with overlapping autoimmune diseases, liver diseases other than hepatitis B, or other comorbidities that could affect RA treatment (e.g., cardiovascular diseases, chronic kidney diseases, interstitial lung disease, diabetes, or previous malignancy within five years) were excluded. Forty patients with HBsAg-positive RA were finally enrolled in the study. We included a control group that comprised 112 age-matched, sex-matched, and entry-time-matched RA patients with negative HBsAg and negative hepatitis B core antibody (HBcAb) using propensity score matching.

Collection of study data

Baseline and longitudinal data of each participant were retrospectively collected at all visits from the date of entry to 31 March 2015. An electronic standardized abstraction form was used for data collection. Baseline data included demographic data, date of RA symptom onset, presence of erosions, and previous medication use. The modified Sharp/van der Heijde (mSvH) scoring system was used to quantify radiologic damage. Because X-ray data were insufficient, only hand X-rays at baseline were used in the assessment. Rheumatoid factor (RF) was measured by immunoturbidimetric assay (Roche/Hitachi Modular P, Roche Diagnostics, Mannheim, Germany; positivity ≥ 15 IU/mL). Anti-cyclic citrullinated peptide antibodies (ACPA) were detected using a chemiluminescent microparticle immunoassay (Architect, Abbott Laboratories, Abbott Park, IL, USA; positivity ≥ 5 U/mL). The disease activity score for 28 joints with three variables (DAS28-3), tender joint counts, swollen joint counts, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), liver function test as measured by alanine aminotransferase (ALT) in units/liter, and RA medication prescription were collected at baseline and updated at every visit. Because patient global assessment data were not collected, DAS28-3 was used as a disease activity marker.
In HBsAg-positive RA patients, prescription of antiviral agents for hepatitis B, purpose of antiviral use (prophylactic or therapeutic), HBsAg positivity, and HBV DNA data were collected from follow-up visits. Characterization of hepatitis B was done at baseline and at every visit to the hepatology clinic. The “inactive HBsAg carrier state” is characterized by HBsAg positivity for > 6 months, serum HBV DNA titer of < 20,000 IU/mL in HBeAg-positive patients or of < 2,000 IU/mL in HBeAg-negative patients and persistently normal ALT levels. “Chronic hepatitis B (CHB)” is characterized by HBsAg positivity for > 6 months, serum HBV DNA titer of > 20,000 IU/mL in HBeAg-positive patients or of > 2,000 IU/mL in HBeAg-negative patients, and persistent or intermittent elevation in ALT levels. Development of hepatocellular carcinoma and reactivation of hepatitis B were also assessed. HBV reactivation was defined by a > 10-fold (1 log_{10} IU/mL) rise in HBV DNA level when compared with the baseline value.

**Statistical analysis**
For selection of control group, propensity score matching was performed using age, sex, and entry time, with a 1:3 case-control ratio. The Kolmogrov-Smirnov and Shapiro-Wilk tests were used to check normality of metric data. For data with a normal distribution, the mean ± standard deviation (SD) is shown, and we applied Student's t-tests for comparisons. For non-normally distributed data, we indicate the median (interquartile range) and used the Wilcoxon rank sum test. Categorical variables were compared using χ² or Fisher’s exact tests. Paired t-test for normally distributed data and Wilcoxon signed rank test for non-normally distributed data were used to compare RA disease activity markers and ALT level at the end of follow-up with those at study entry. Generalized estimating equations (GEEs) were used to assess the association between HBsAg positivity and RA disease activity markers/medication use over time. In GEE models, data were adjusted for visit date and further adjusted for age, sex, and duration of RA. All statistical analyses were performed using SAS, version 9.4 (SAS Institute Inc., Cary, NC, USA).

**Ethics statement**
The present study protocol was reviewed and approved by the Institutional Review Board of Samsung Medical Center (IRB No. 2015-09-069). The requirement for informed consent was waived since the study involved a minimum risk to the enrolled patients in this retrospective study and no identifiable information was used.

**RESULTS**
The study sample consisted of 40 patients with HBsAg-positive RA and 112 patients with HBsAg-negative RA. A description of patient characteristics at baseline is provided in Table 1. Median age was 43 (interquartile range [IQR], 37–53) years, and women constituted 76.3% of the total study population. There were no significant differences between groups with regard to demographics RA disease characteristics including RF positivity, ACPA positivity, and the presence of erosions; instruments reflecting RA disease activity; or previous medication use at baseline. Methotrexate tended to be less frequently prescribed for HBsAg-positive patients, but the difference was not statistically significant. Leflunomide, cyclosporine, azathioprine, and biologic agents including tumor necrosis factor α (TNF-α) inhibitors were less commonly used in the study population, and there were no significant differences in the use of these medications between groups at baseline.

At baseline, the HBsAb-positive rate was significantly higher in the HBsAg-negative group than the HBsAg-positive group (49.1% vs. 7.5%; P < 0.001). No differences were noted in
In HBsAg-positive patients, the positive rate for HBcAb was 96.9% (n = 31) and that for HBeAg was 19.4% (n = 7). HBV DNA data were available in 35 patients (87.5% of HBsAg-positive patients); HBV DNA positivity was 37.1% (n = 13). Ten percent of HBsAg-positive patients received antiviral treatment (n = 4). Among 40 patients who had HBsAg, 28 patients were classified as inactive carriers and 9 patients were classified as having CHB. Three patients had been diagnosed with liver cirrhosis.

The median number of visits per subject was 28 (IQR, 19–61) in the HBsAg-positive group and 27 (IQR, 16–45) in the HBsAg-negative group (P = 0.175). The median follow-up duration per subject was 2,361 (IQR, 1,462–4,326) days in the HBsAg-positive group and 1,863 (IQR, 1,133–3,659) days in the HBsAg-negative group, was similar between these groups (P = 0.119).

We used GEE regression analysis to determine the effects of time and HBsAg-positivity on RA disease activity markers and ALT (Table 2). All RA disease activity markers were negatively associated with time (P < 0.05 for all models). Swollen joint count was the only instrument that showed a significant interaction between time and HBsAg-positivity in both unadjusted and adjusted models (β-estimate, 8.18; 95% confidence interval [CI], 1.40–14.96; P = 0.018 in the unadjusted model; β-estimate, 7.91; 95% CI, 1.41–14.41; P = 0.017 in the adjusted model). We observed a significant effect of HBsAg-positivity on the relationship between time and DAS28-3 (β-estimate, 2.79; 95% CI, 0.18–5.57; P = 0.026), but this interaction did not remain significant after adjustment for age, sex, and duration of RA. For tender joint count, ESR, and CRP levels, there were no interaction between time and HBsAg-positivity. ALT levels did not change significantly with time or with HBsAg-positivity.

At the end of follow-up, disease activity markers were improved compared with baseline (Fig. 1). There were no significant differences in disease activity markers between HBsAg-positive and HBsAg-negative patients.

### Table 1. Baseline characteristics of HBsAg-positive and HBsAg-negative RA patients

| Characteristics                  | HBsAg positive (n = 40) | HBsAg negative (n = 112) | P value |
|----------------------------------|-------------------------|--------------------------|---------|
| Age, yr                          | 48.0 (37.3–56.5)        | 43.0 (36.3–51.0)         | 0.139   |
| Sex (female)                     | 29 (72.5)               | 87 (77.7)                | 0.508   |
| RA disease duration, mon         | 30.5 (6.0–84.5)         | 36.5 (9.0–99.0)          | 0.397   |
| RF positivity                    | 29 (72.5)               | 89 (79.5)                | 0.364   |
| ACPA positivity                  | 18 (45)                 | 51 (45.5)                | 0.848   |
| Erosions                         | 30 (75)                 | 71 (63.4)                | 0.442   |
| Tender joint count               | 3.5 (1.0–10.5)          | 4.0 (2.0–8.8)            | 0.456   |
| Swollen joint count              | 3.0 (1.0–6.8)           | 3.0 (2.0–7.0)            | 0.198   |
| ESR, mm/hr                       | 37.0 (18.5–69.0)        | 38.0 (20.0–56.0)         | 0.689   |
| CRP, mg/dL                       | 1.1 (0.2–2.9)           | 0.6 (0.2–2.0)            | 0.438   |
| DAS28-3, mean ± SD               | 4.31 ± 1.21             | 4.32 ± 1.23              | 0.965   |
| Modified sharp score (0–280)     | 9.0 (2.0–28.5)          | 2.5 (0.0–24.0)           | 0.164   |
| Previous medication use          |                         |                          |         |
| Corticosteroids                  | 18 (45.0)               | 49 (43.8)                | 0.891   |
| Methotrexate                     | 10 (25.0)               | 30 (26.8)                | 0.826   |
| Hydroxychloroquine               | 5 (12.5)                | 30 (26.8)                | 0.065   |
| Sulfasalazine                    | 10 (25.0)               | 17 (15.2)                | 0.163   |
| Number of previous used DMARDs   | 0 (0–2)                 | 0 (0–2)                  | 0.841   |
| ALT, U/L                         | 15.5 (12.0–20.8)        | 13.5 (10.0–19.0)         | 0.170   |

Data are presented as median with IQR or number (%). HBsAg = hepatitis B virus surface antigen, RA = rheumatoid arthritis, RF = rheumatoid factor, ACPA = anti-cyclic citrullinated peptide antibodies, ESR = erythrocyte sedimentation rate, CRP = C-reactive protein, DAS28-3 = disease activity score for 28 joints with three variables, DMARD = disease-modifying antirheumatic drug, ALT = alanine aminotransferase, IQR = interquartile range.

*Data were available for 33 and 100 patients in the HBsAg-positive group and the HBsAg-negative group, respectively; * Patients who had already been diagnosed and treated with RA at another hospital.
When all study visits were analyzed, methotrexate was less frequently used in HBsAg-positive patients (odds ratio [OR], 0.09; 95% CI, 0.04–0.19; \(P<0.001\); [Fig. 2]). HBsAg-positive patients were more likely to be prescribed sulfasalazine (OR, 3.67; 95% CI, 1.94–6.95; \(P<0.001\)) and cyclosporine (OR, 3.57; 95% CI, 1.33–9.54; \(P=0.011\)). On unadjusted analysis, tacrolimus was more frequently used in HBsAg-positive patients, but after adjusting for age, sex, and duration of RA, this difference was not significant. Hydroxychloroquine was prescribed somewhat more often in HBsAg-positive patients, but this difference was not statistically significant. With regard to corticosteroids, leflunomide, and biologic agents including TNF-\(\alpha\) inhibitors, there were no significant differences.

Combination therapy with conventional DMARDs was significantly more frequently applied in HBsAg-positive patients than HBsAg-negative patients (OR, 2.22; 95% CI, 1.19–4.14; \(P=0.012\)); however, there was no significant difference in the use of combination therapy with biologic agents between the two groups (OR, 0.76; 95% CI, 0.14–4.14; \(P=0.755\)). The frequency of intraarticular injection of corticosteroids was higher in HBsAg-positive patients than HBsAg-negative patients (median 2, IQR, 1–8 vs. 1, IQR, 0–3; \(P=0.001\)) during the study period.

Among 40 patients with HBsAg-positivity, 15 patients (37.5%) received antiviral treatment. The purpose of antiviral treatment was prevention of hepatitis reactivation in 8 patients and therapy for hepatitis or cirrhosis in 7 patients. During the study period, one patient with CHB at baseline was newly diagnosed with liver cirrhosis and another patient who was an inactive carrier at baseline was newly diagnosed with CHB (Fig. 3). Two incident cases of hepatocellular carcinoma were observed.
Hepatitis reactivation occurred in 4 HBsAg-positive RA patients (10%, Table 3). One patient was an inactive carrier, and the other patients had CHB at baseline. Among the patients who experienced HBV reactivation, only one patient had received previous antiviral treatment at baseline, but the patient exhibited lower adherence to drug. The HBV DNA level decreased.
below the detection limit after antiviral treatment in three of these patients except one patient lost to follow-up. There were no cases of hepatic failure or death.

**DISCUSSION**

In this study, we investigated the differences in disease characteristics, treatment patterns and changes in disease activity according to concomitant HBV infection. Although previous studies have described disease activity in RA with HBV infection, these studies were carried out at a single time point, examined use of specific drugs, or did not include a control group.\(^{18-20}\) In translational research on patients with RA and concomitant hepatitis B infection, the functional activity of complement was further reduced in patients with hepatitis, and levels of complement were associated with the course of RA.\(^{21}\) Therefore, we conducted this study to determine whether HBV infection affects RA disease activity. To the best of our knowledge,
this is the first study comparing differences in disease activity markers and treatment pattern according to HBsAg-positivity in RA patients using long-term follow-up data.

One study reported that HBV infection did not have any significant association with disease activity or joint destruction in RA. Similarly, our analysis of baseline disease activity data revealed no differences between HBsAg-positive and HBsAg-negative patients. On regression analysis of longitudinal data, RA disease activity had a significant negative correlation with time, which likely resulted from effective RA treatment during the study period. Of the markers representing disease activity, tender joint counts, ESR, and CRP levels showed no significant differences between groups, while swollen joint counts were significantly different. Although joint counts are used as the primary measure of disease activity of RA, a number of limitations of joint counts have been described in several publications. Joint counts may have more noise and more instability than would be expected due to poor reducibility. Furthermore, joint counts showed relatively lower efficiency than global estimates and physical function in comparing active and control treatments in clinical trials. Thus, variation in swollen joint counts, without observed differences in any other measures, was not considered to indicate a meaningful difference in RA disease activity between HBsAg-positive and HBsAg-negative patients.

When all study visits were analyzed, methotrexate was prescribed significantly less frequently for HBsAg-positive patients. Such results were interpreted as reflecting real-world practice based on the ACR guidelines, in which methotrexate is contraindicated for CHB. Sulfasalazine was used more frequently in HBsAg-positive patients because it was considered relatively safer than other DMARDs. Hydroxychloroquine was prescribed for almost all HBsAg-positive patients, but was also frequently prescribed for HBsAg-negative patients, and thus there was no significant difference between groups. The observed difference in combination therapy with conventional DMARDs according to HBsAg-positivity is likely related to the difference in drugs frequently used, as demonstrated in this study. Sulfasalazine and hydroxychloroquine are frequently used as a combination therapy because these drugs are thought to have less disease-modifying effects than methotrexate monotherapy. The use of systemic corticosteroids was similar in both groups, whereas the frequency of intraarticular corticosteroid injection was higher in the HBsAg-positive group. Intraarticular corticosteroid injection may have systemic effects, but the risk of HBV reactivation is substantially less than 1% of cases. For this reason, local control using intraarticular corticosteroids seems to have been preferred in cases where systemic immunosuppressants are difficult to use, such as hepatitis B carriers.

The results of this study did not show any differences in the use of biologic agents based on the presence of HBsAg. However, since the number of patients included in the study was small, further studies are warranted on the effects of HBsAg positivity on biologic treatment. Recent retrospective studies have reported that biologic DMARDs are not significantly different from conventional DMARDs in terms of HBV reactivation with no significant differences in clinical outcomes even after HBV DNA reactivation. However, one review did classify biologics such as TNF inhibitors as a high-risk group for HBV reactivation, so further large-scale studies are needed to confirm the effects of biologic agents on HBV reactivation.

There were no statistical differences in serum transaminase level, according to HBsAg-positivity. These results suggest that safe treatment of RA is possible in patients with...
concomitant chronic HBV infection, if close monitoring of liver function and frequent assessment of hepatitis state are combined with treatment modification.

HBV reactivation was reported in 4 patients who were positive for HBV DNA at baseline. A high level of baseline HBV DNA is a risk factor for HBV reactivation after immunosuppressive therapy. Previous studies demonstrated that preemptive antiviral therapy was effective in HBsAg-positive patients. Current guidelines recommend that HBsAg-positive patients should receive preemptive antiviral administration during immunosuppressive therapy regardless of HBV DNA levels. In this study, 37.5% of patients received antiviral therapy, lower than the expected proportion. There are two possible explanations for this situation. First, there is the problem of the expense of antiviral treatment, because Korean national health insurance does not cover preemptive use of antiviral agents. Second, in some patients, drugs with low hepatotoxicity, like hydroxychloroquine and sulfasalazine, were sufficient for control of disease activity and prophylactic antiviral medication was not necessary.

Among the 15 patients receiving antiviral agents, one patient experienced HBV reactivation. The patient who experienced reactivation while taking an antiviral agent showed poor compliance with the prescribed regimen, whereas no patients experienced HBV reactivation during adequate antiviral therapy. These results support previous publications, which described the increased HBV reactivation risk after discontinuation of antiviral agents. To maximize the effect of antiviral agent, medication adherence must be monitored and interventions to improve adherence should be considered.

Our study has several limitations that should be considered. First, since we conducted the study in a retrospective manner, the duration of follow-up and the interval of visits were quite variable, and some data were missing. For the detection of relationships, regression analysis using GEE models was conducted. GEE has several advantages in the analysis of longitudinal data, including that it allows the use of all available data. Second, patient-reported outcomes and global assessments were not included in analysis due to insufficient information. Differences in patient-reported outcomes according to concomitant HBV infection need to be addressed. Third, because this study was conducted at a single center and exclusion criteria were strictly applied, there are limitations with respect to generalizability. Nonetheless, the effect of chronic HBV infection itself was forcefully evaluated by excluding other comorbidities that may affect the treatment of RA.

In conclusion, our findings suggest that HBsAg-positivity affected the selection of medication to treat RA, but did not show a clear association with changes in disease activity. In RA patients with concomitant hepatitis B infection, safe and effective treatment of RA is possible through medication adjustment and close monitoring of liver function and disease activity.

REFERENCES

1. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ort JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet 2015;386(10003):1546-55.

2. Dougados M, Soubrier M, Antunez A, Balint P, Balsa A, Buch MH, et al. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann Rheum Dis 2014;73(1):62-8.
3. Aithal GP. Hepatotoxicity related to antirheumatic drugs. *Nat Rev Rheumatol* 2011;7(3):139-50.

4. Ruderman EM. Overview of safety of non-biologic and biologic DMARDs. *Rheumatology (Oxford)* 2012;51 Suppl 6:v37-43.

5. Curtis JR, Beukelman T, Onofrei A, Cassell S, Greenberg JD, Kavanaugh A, et al. Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and/or leflunomide. *Ann Rheum Dis* 2010;69(1):43-7.

6. Tamori A, Koike T, Goto H, Wakitani S, Tada M, Morikawa H, et al. Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts. *J Gastroenterol* 2011;46(4):556-64.

7. Tan J, Zhou J, Zhao P, Wei J. Prospective study of HBV reactivation risk in rheumatoid arthritis patients who received conventional disease-modifying antirheumatic drugs. *Clin Rheumatol* 2012;31(8):1169-75.

8. Ryu HH, Lee EY, Shin K, Choi IA, Lee YJ, Yoo B, et al. Hepatitis B virus reactivation in rheumatoid arthritis and ankylosing spondylitis patients treated with anti-TNFα agents: a retrospective analysis of 49 cases. *Clin Rheumatol* 2012;31(6):931-6.

9. Urata Y, Uesato R, Tanaka D, Kowatari K, Nitobe T, Nakamura Y, et al. Prevalence of reactivation of hepatitis B virus replication in rheumatoid arthritis patients. *Mod Rheumatol* 2011;21(1):16-23.

10. Burton MJ, Curtis JR, Yang S, Chen L, Singh JA, Mikuls TR, et al. Safety of biologic and nonbiologic disease-modifying antirheumatic drug therapy in veterans with rheumatoid arthritis and hepatitis B virus infection: a retrospective cohort study. *Arthritis Res Ther* 2015;17(1):136.

11. Shin K, Jang H, Jang WM, Lee JS, Song YW. Treatment of rheumatoid arthritis patients with chronic hepatitis B: analysis of Korean National Health Insurance claims data. *J Rheum Dis* 2013;20(1):24-9.

12. van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. *J Rheumatol* 2000;27(1):261-3.

13. Balsa A, Carmona L, González-Alvaro I, Belmonte MA, Tenas X, Sannart M, et al. Value of disease activity score 28 (DAS28) and DAS28-3 compared to American College of Rheumatology-defined remission in rheumatoid arthritis. *J Rheumatol* 2004;31(1):40-6.

14. Prevoo ML, van ’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. *Arthritis Rheum* 1995;38(1):44-8.

15. Lok AS, McMahon BJ. Chronic hepatitis B. *Hepatology* 2007;45(2):507-39.

16. Hoofnagle JH. Reactivation of hepatitis B. *Hepatology* 2009;49(S Suppl):S156-65.

17. Zou CJ, Zhu LJ, Li YH, Mo YQ, Zheng DH, Ma JD, et al. The association between hepatitis B virus infection and disease activity, synovitis, or joint destruction in rheumatoid arthritis. *Clin Rheumatol* 2013;32(6):787-95.

18. Kim PS, Ho GY, Prete PE, Furst DE. Safety and efficacy of abatacept in eight rheumatoid arthritis patients with chronic hepatitis B. *Arthritis Care Res (Hoboken)* 2012;64(8):1265-8.

19. Ming-Xu H, Chen M, Cai Y, Yan-Jia H. Clinical outcomes of low-dose leflunomide for rheumatoid arthritis complicated with hepatitis B virus carriage and safety observation. *Pak J Med Sci* 2015;31(2):320-4.
21. Balabanova RM, Shekshina EV, Kozlov LV. Immunological features of rheumatoid arthritis in patients infected with viruses of hepatitis B, C and in patients with cryoglobulinemia. Ter Arkh 2004;76(11):74-7.

22. Pincus T. Limitations of a quantitative swollen and tender joint count to assess and monitor patients with rheumatoid arthritis. Bull NYU Hosp Jt Dis 2008;66(3):216-23.

23. Eberl DR, Fasching V, Rahlis V, Schleyer I, Wolf R. Repeatability and objectivity of various measurements in rheumatoid arthritis. A comparative study. Arthritis Rheum 1976;19(6):1278-86.

24. Lassere MN, van der Heijde D, Johnson KR, Boers M, Edmonds J. Reliability of measures of disease activity and disease damage in rheumatoid arthritis: implications for smallest detectable difference, minimal clinically important difference, and analysis of treatment effects in randomized controlled trials. J Rheumatol 2001;28(4):892-903.

25. Pincus T, Amara I, Segurado OG, Bergman M, Koch GG. Relative efficiencies of physician/assessor global estimates and patient questionnaire measures are similar to or greater than joint counts to distinguish adalimumab from control treatments in rheumatoid arthritis clinical trials. J Rheumatol 2008;35(2):201-5.

26. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59(6):762-84.

27. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012;64(5):625-39.

28. Habib GS. Systemic effects of intra-articular corticosteroids. Clin Rheumatol 2009;28(7):749-56.

29. Perrillo RP, Gish R, Falck-Ytter YT. American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 2015;148(1):221-244.e3.

30. Chen MH, Liu CY, Tsai CY, Huang DF, Lin HY, et al. Hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologics treatment. J Infect Dis 2017;215(4):566-73.

31. Nakamura J, Nagashima T, Nagatani K, Yoshio T, Iwamoto M, Minota S. Reactivation of hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs. Int J Rheum Dis 2016;19(5):470-5.

32. Loomba R, Liang TJ. Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions. Gastroenterology 2017;152(6):1297-309.

33. Yeo W, Zee B, Zhong S, Chan PK, Wong WL, Ho WM, et al. Comprehensive analysis of risk factors associating with hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer 2004;90(7):1306-11.

34. Shouval D, Shibolet O. Immunosuppression and HBV reactivation. Semin Liver Dis 2013;33(2):167-77.

35. Lau GK, Yiu HH, Fong DY, Cheng HC, Au WY, Lai LS, et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 2003;125(6):1742-9.

36. Long M, Jia W, Li S, Jin L, Wu J, Rao N, et al. A single-center, prospective and randomized controlled study: can the prophylactic use of lamivudine prevent hepatitis B virus reactivation in hepatitis B s-antigen seropositive breast cancer patients during chemotherapy? Breast Cancer Res Treat 2011;127(3):705-42.

37. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50(3):661-2.
38. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. *J Hepatol* 2012;57(1):167-85.

39. Korean Association for the Study of the Liver. KASL clinical practice guidelines: Management of chronic hepatitis B. *Clin Mol Hepatol* 2012;18(2):109-62.

40. Mo YQ, Liang AQ, Ma JD, Chen LF, Zheng DH, Schumacher HR, et al. Discontinuation of antiviral prophylaxis correlates with high prevalence of hepatitis B virus (HBV) reactivation in rheumatoid arthritis patients with HBV carrier state: a real-world clinical practice. *BMC Musculoskelet Disord* 2014;15(1):449.